期刊文献+

原发性肝癌射频消融后肿瘤残留分析 被引量:21

Risk factors of partial response of primary liver cancer after percutaneous radiofrequency ablation
原文传递
导出
摘要 目的探讨原发性肝癌射频消融后肿瘤残瘤(即不完全消融)的相关影响因素。方法1999月12月至2007年4月,上海第二军医大学附属东方肝胆外科医院共对1341例原发性肝癌病人的2696个肿瘤实施了超声引导下经皮射频消融治疗。术后1-2个月内复查,统计术后肿瘤残留发生率。结果1142例病人2331个肿瘤得到有效复查资料。132例(11.6%)病人的192个(8.2%)肿瘤射频消融后发生活性组织残留。肿瘤大小、部位、生长方式、术前TACE、射频发生器类型以及超声定位清晰度等指标与术后肿瘤组织残留显著相关,分别为p=0.000,P:0.004,p=0.014,P=0.001和P=0.000。Logistic多因素回归分析表明,只有肿瘤大小、部位、生长方式以及术前TACE是肝癌射频消融后活性组织残留的独立影响因素。结论合理选择肿瘤大小、部位和射频发生器,精确超声定位,术前实施TACE等可降低射频消融后不完全消融率,减少术后肿瘤残留。 Objective To determine the risk factors of the partial response of primary liver cancer after percutaneous radiofrequency ablation (PRFA). Methods From December 1999 to April 2007,we treated 2331 tumors in 1142 cases of primary liver cancer with PRFA. The 192 of the 2331 tumors achieved a partial response (PR). We investigated the relationship between 10 pretreatment factors and the partial response of PRFA. Results The overall partial response rate was 8.2% within 2 months after PRFA. Tumor size, tumor location, growth pattern, TACE before PRFA, the electrode pattern and legible orientation of tumor under ultrasound were significantly associated with a higher partial response rate(P=0. 000,P=0. 004,P=0. 014,P=0. 001 and P=0. 000, respectively). However, only the tumor size, tumor location, growth pattern and TACE before PRFA were found to be independent risk factors for the partial response of primary liver cancer after percutaneous radiofrequency ablation by Logistic regression model. Conclusion The tumor size, tumor location, growth pattern of tumor and TACE before PRFA treatment influence the local efficacy of PRFA for primary liver cancer.
出处 《中华肝胆外科杂志》 CAS CSCD 北大核心 2009年第4期254-258,共5页 Chinese Journal of Hepatobiliary Surgery
关键词 肝细胞 射频消融 肿瘤残留 Carcinoma,hepatocellular Percutaneous radiofrequency ablation Partial response
  • 相关文献

参考文献5

二级参考文献86

  • 1Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology, 2000,214:761-768.
  • 2Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrosPective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology, 2000,32: 1224-1229.
  • 3Lau WY, Leung TW, Yu SC, et al. Percutaneous local ablative therapy for hepatocellular carcinoma:a review and look into the future. Ann Surg, 2003,237: 171-179.
  • 4Orlando A, D'Antoni A, Camma C, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a validated prognostic model. Am J Gastroenterol. 2000, 95: 2921-2927.
  • 5Livraghi T, Goldberg SN, Lazzaroni S, et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology, 1999,210: 655-661.
  • 6Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer.Am J Roentgenol,1996,167:759-768.
  • 7Rossi S, Buscarini E, Garbagnati F, et al. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode . Am J Roentgenol, 1998,170: 1015-1022.
  • 8Bosch FX. Global epidemiology of hepatocellular carcinoma.In: Okuda K. Tabor E. Liver Cancer. New York: Churchill Livingstone 1997:13-28.
  • 9Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19:271.
  • 10Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61:1942-1956.

共引文献244

同被引文献248

引证文献21

二级引证文献165

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部